The earnings call presented a strong focus on revenue growth and strategic repositioning, with significant progress in financial management and pipeline development. However, challenges remain in the adoption of LOQTORZI in community settings and competitive pressures in pipeline development. The positive aspects of revenue growth and strategic alignment outweigh the challenges.

Company Guidance

During Coherus Oncology's Q2 2025 earnings call, CEO Dennis M. Lanfear provided guidance on the company's strategic focus and anticipated growth. He highlighted the approval and commercial success of their next-generation PD-1 inhibitor, LOQTORZI, which saw a 36% increase in net revenue to $10 million in Q2 2025, driven by physician adoption and updated NCCN guidelines. Lanfear emphasized the potential of their pipeline assets, including CHS-114 and casdozokitug, to expand market opportunities, with second-line head and neck cancer and first-line hepatocellular carcinoma being key focuses. The company projects total 2025 revenues between $40 million and $50 million and maintains a strong balance sheet with $238 million in cash, ensuring operations through 2026.

LOQTORZI Revenue Growth

LOQTORZI's net revenue in the second quarter grew 36% over Q1 2025 to $10 million, marking a 65% increase year-over-year.

Improved Financial Position

Coherus Oncology ended Q2 with $238 million in cash and investments, projecting sufficient cash to provide runway through 2026.

Strategic Repositioning as Coherus Oncology

The company has completed its strategic repositioning to focus on oncology, aligning its mission and commercial strategy.

Promising Pipeline Developments

The company highlighted the development of CHS-114 and casdozokitug, noting potential best-in-class attributes and significant market opportunities.

Cost Management and Savings

Achieved additional progress on managing cost structure with expected annual savings of approximately $30 million from headcount reductions.

Coherus Biosciences (CHRS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CHRS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.33 / -	-0.09	―	―	―
Aug 07, 2025	2025 (Q2)	-0.22 / -0.39	-0.11	-254.55% (-0.28)	―
May 12, 2025	2025 (Q1)	-0.30 / -0.41	0.83	-149.40% (-1.24)	―
Mar 10, 2025	2024 (Q4)	-0.31 / -0.44	-0.71	38.03% (+0.27)	―
Nov 06, 2024	2024 (Q3)	-0.16 / -0.09	-0.41	78.05% (+0.32)	―
Aug 08, 2024	2024 (Q2)	-0.25 / -0.11	-0.49	77.55% (+0.38)	―
May 09, 2024	2024 (Q1)	-0.25 / 0.83	-0.96	186.46% (+1.79)	―
Mar 13, 2024	2023 (Q4)	-0.20 / -0.71	-0.76	6.58% (+0.05)	―
Nov 06, 2023	2023 (Q3)	-0.39 / -0.41	-1.11	63.06% (+0.70)	―
Aug 02, 2023	2023 (Q2)	-0.63 / -0.49	-0.65	24.62% (+0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CHRS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.88	$0.82	-6.82%
May 12, 2025	$1.02	$0.82	-19.61%
Mar 10, 2025	$1.04	$1.05	+0.96%
Nov 06, 2024	$0.72	$0.82	+13.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Coherus Biosciences (CHRS) report earnings?

Coherus Biosciences (CHRS) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Coherus Biosciences (CHRS) earnings time?

Coherus Biosciences (CHRS) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CHRS EPS forecast?

CHRS EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing